Articles tagged with Pancreatic Cancer
Scientists have found a way to break down the resistance of mice with neuroendocrine pancreatic cancer to checkpoint blockade immunotherapy. A new drug combination, PD1-IL2v and anti-PD-L1, enhances anti-tumor immunity by stimulating specific T cells and reprogramming macrophages, leading to increased survival rates in tumor-bearing mice.
Researchers at Cima Universidad de Navarra identified LAMC2 as a key gene in pancreatic cancer development. Inhibiting this gene, combined with existing drugs, increases antitumor effect in 3D models.
Researchers at MD Anderson Cancer Center have discovered a novel triple immunotherapy combination targeting checkpoints in T cells and myeloid suppressor cells, improving anti-tumor responses and survival rates in preclinical models of pancreatic cancer. The study found that neutralizing specific immunosuppressive mechanisms dramatical...
Researchers developed predictive models using serum microRNAs to identify patients at risk of requiring early palliative care. The study used serum samples from 178 patients with various types of cancer and found that miRNA-based models had higher accuracy than clinical models in predicting referral to a palliative care unit.
The CodeBreaK 100 trial demonstrates meaningful anticancer activity with sotorasib in heavily pretreated patients with KRAS G12C-mutated metastatic pancreatic cancer. The results show an objective response rate of 21.1% and a median time-to-response of 1.5 months.
The study reveals that SETD1A overexpression is associated with poorer disease-free survival in pancreatic cancer patients. Artificially cultured cells showed increased cell growth and migration when SETD1A levels were overexpressed, while knocking down SETD1A expression led to decreased RUVBL1 gene expression.
Scientists at UCSF have engineered T cells to produce a potent anti-cancer cytokine that only activates in tumor cells, eliminating melanoma and pancreatic cancer in mice. The treatment uses IL-2, which supercharges T cells to kill cancer cells while protecting against infection, offering a promising new strategy for fighting hard-to-t...
A new study has identified a potential therapy for metastatic colon cancer by targeting the molecule hyaluronan, which accumulates in tumors and shuts down immune cells that can kill tumor cells. The experimental therapy, hyaluronidase, shrinks tumors and allows immune cells to attack tumor cells.
A new clinical trial has found that chemotherapy before surgery significantly improves 1-year survival rates for patients with borderline resectable pancreatic cancer. The study, led by the University of Liverpool, compared immediate surgery with short-course neoadjuvant therapy and found a significant survival benefit.
A nationwide retrospective study showed that adjuvant chemotherapy after neo-adjuvant chemotherapy and surgery significantly improved overall survival in patients with pancreatic adenocarcinoma, regardless of lymph node status or resection margins. The study included nearly 900 patients and was published in JAMA Oncology.
Researchers visualized the (pro)renin receptor's protein binding site and found hand-shaped grooves allowing for multiple protein binding. The study provides new insight into disease pathogenesis and aids in exploring novel treatments.
Researchers developed a small molecule inhibitor that successfully shrunk tumors or stopped cancer growth in preclinical models of pancreatic cancer. The drug, MRTX1133, not only targets cancer cells but also cooperates with the immune system to produce a durable response to treatment.
Researchers at VCU Massey Cancer Center discovered the inactivation of NF1 as a potential genetic driver for pancreatic cancer. The study suggests that targeting NF1 could create vulnerabilities for therapeutic advantage in mutant KRAS-bearing tumors.
Researchers at University of Pittsburgh have designed novel nanoparticles that co-deliver a chemotherapy drug and a novel immunotherapy, shrinking tumors in mouse models of colon and pancreatic cancer. The therapy silences a gene involved in immunosuppression by blocking Xkr8 protein distribution on the cell membrane.
A recent study found that MRI-guided adaptive radiation therapy, also known as SMART, has shown promising safety and patient outcomes data for treating locally advanced and borderline resectable pancreatic cancer. The study, led by Henry Ford Health, reported no incidence of acute grade 3 or higher gastrointestinal toxicity, with preli...
The ESMO Asia Congress 2022 will focus on the latest scientific and clinical advances in oncology, with a special emphasis on the Asia-Pacific region. Media representatives can register for coverage through the official media registration form.
A new study by Cedars-Sinai investigators has identified risk factors for developing diabetes in people with chronic pancreatitis, including smoking and being overweight. The findings suggest that models can be built to predict diabetes risk, allowing clinicians to connect patients with weight loss or smoking cessation programs.
Researchers found that a new drug inhibiting GRP78 effectively reduces SARS-CoV-2 replication in human lung cells. The drug also shows potential in treating certain types of cancer by suppressing mutant KRAS proteins.
A specialized triage algorithm, ROCA test, enables earlier stage diagnosis in women deferring preventive surgery, saving NHS costs. The approach results in fewer major surgical interventions and lower risk of wider disease spread.
In the ARROS-1 trial, 48% of patients achieved partial responses to NVL-520, with responses seen across all dose levels and in heavily pre-treated patients. The treatment also showed promise for brain metastases, with three out of three patients experiencing measurable response or no emergence of new metastases.
A Phase Ib clinical trial found that sequential administration of PARP inhibitor olaparib and WEE1 inhibitor adavosertib is safe and well-tolerated, with promising signs of anti-tumor activity in patients with advanced cancers driven by DNA damage response mutations. The combination showed durable responses in patients with resistant c...
Researchers have found a drug that targets the key, cancer-causing gene MYC has been able to inhibit its function safely and effectively. Eight out of 12 patients showed stabilisation of disease after treatment with OMO-103, with one patient experiencing a reduction in tumour-derived DNA circulating in the blood stream.
Researchers at Duke University have developed a novel treatment that combines internal radiation and chemotherapy to eliminate tumors in 80% of mice with pancreatic cancer. The approach uses a gel-like depot implanted with radioactive iodine-131, which deposits beta radiation directly into the tumor without affecting surrounding tissue.
Scientists at the University of Florida have identified two small molecules that inhibit precancerous cell progression and reverse a key process involved in pancreatic cancer progression. This discovery could lead to earlier treatments and improved survival rates for patients with pancreatic cancer.
Virginia Tech researchers found that a common oral bacterium, Fusobacterium nucleatum, drives pancreatic cancer cell proliferation and migration. The bacterium can infect normal pancreatic tissue cells, stimulating nearby cancer cells to grow and spread rapidly.
Researchers developed an antibody-based treatment that targets cadherins on circulating tumor cells, eliminating them in mouse models of breast and pancreatic cancer. The therapy shows promise in preventing cancer metastasis, a leading cause of cancer-related deaths.
Scientists at The Wistar Institute have discovered a correlation between mitochondrial dysfunction and aggressive pancreatic cancer. An 11-gene signature indicative of mitochondrial reprogramming in tumors has been identified, which correlates with poor patient outcomes and treatment resistance.
Researchers propose an optical imaging system for real-time hypoxia imaging in cancer treatment. The technique utilizes protoporphyrin IX to enhance contrast between tumors and healthy tissues, allowing for more effective surgical removal.
A study found that over a third (36%) of post-imaging pancreatic cancer cases were potentially avoidable, highlighting poor detection rates. Researchers analyzed patient records to develop an algorithm to categorize missed cases and identify the most likely explanation for why they were missed.
Researchers from Rutgers Cancer Institute have identified specific microorganisms associated with inflammation and poor survival in pancreatic tumors. These microbial signatures can be used as new targets for earlier diagnosis or treatment of the fourth leading cause of cancer death.
Researchers developed a novel organoid model to study pancreatic cancer cells' growth and arrangement. The model provides insight into the three-dimensional structure of tumors, enabling tracking of individual growth stages, cell divisions, and gene expression patterns.
A new study found that the organization of different types of immune cells within pancreatic tumors is associated with patient outcomes. Immune cells called IL-10+ myelomonocytes tend to be located close to specific T cell types, which may affect cancer treatment responses.
Researchers found that the quality and mix of collagen in pancreatic ductal adenocarcinoma tumors affects prognosis. Patients with tumors containing cleaved Collagen I experienced poor survival prospects, while those with non-cleaved Collagen I had better outcomes.
Researchers at UNC Lineberger Comprehensive Cancer Center have found a way to overcome barriers limiting cancer immunotherapies. They discovered that activating the STING protein can increase regulatory B cells, which suppress anti-cancer immunity.
A new genetic test called PancreaSeq accurately classifies pancreatic cysts as potentially cancerous or benign, improving the accuracy of diagnoses compared to current guidelines. The test distinguishes between different types of cysts with higher accuracy than traditional forms of surveillance and current pancreatic cyst guidelines.
Cleveland researchers reveal a new strategy to prevent blood clots by targeting overactive neutrophils, reducing clotting risk while minimizing bleeding risk. The findings may be especially impactful for cancer patients who experience blood clot complications.
Researchers at Mayo Clinic Comprehensive Cancer Center have identified a gene marker that may lead to more effective precision treatment for pancreatic ductal adenocarcinoma. The protein METTL16 is correlated with accumulated DNA damage and suppresses DNA repair, suggesting it as a potential biomarker for PARPi treatment.
Researchers found that stress granules are abundant in obesity-related pancreatic cancer and blocking their formation stops cancer growth in animals. The study reveals a potential new direction for developing cancer therapy by targeting stress granule formation.
A new AI tool has been developed to detect pancreatic cancer on CT scans with high accuracy, achieving 90% sensitivity and 96% specificity. The tool's performance is comparable to that of radiologists, offering a promising supplement for early detection and improved treatment outcomes.
Researchers at California NanoSystems Institute developed a nanocarrier that delivers a combination therapy to pancreatic tumors using irinotecan and 3M-052, resulting in improved treatment outcomes and reduced side effects. The simultaneous delivery of the two drugs outperformed separate treatments in mouse models.
In a Phase I/II trial, selpercatinib demonstrated a 44% objective response rate across multiple tumor types, including pancreatic and colorectal cancers. The study found responses regardless of cancer type or prior treatment history, confirming RET fusions as a tissue-agnostic target.
Researchers at Mayo Clinic Comprehensive Cancer Center found that metabolic imaging, combined with traditional treatment response assessment methods, can provide critical information to guide therapy for pancreatic cancer patients. The use of positron emission tomography (PET) with 18-fluorodeoxyglucose (FDG) tracer adds significant pr...
Champalimaud Foundation researchers have developed a new biomarker, IgG-positive EVs, to assess treatment response in pancreatic cancer patients. These extracellular vesicles increase during disease progression and decrease in response to therapy, offering a more reliable tool for evaluating tumour status.
A UCSF-led team reveals that tumor immune microenvironments play a crucial role in the progression of pancreatic cysts to pancreatic cancer. The study suggests that therapies targeting regulatory T cells and myeloid-derived suppressor cells could inhibit malignant progression and treat high-risk disease.
Researchers at UVA have discovered the mechanism behind gene regulation during organ development, shedding light on how genetic material interacts with transcription factors to create different cell types. The study's findings could offer insights into the initiation of certain cancers and inspire new therapeutic development.
A study has revealed two key transition points in the development of pancreatic cancer, shedding light on treatment resistance and possible new therapies. The research provides insights into how normal cells become precancerous and cancerous, as well as a new strategy for checkpoint immunotherapy.
The University of Cincinnati is conducting a study on a potential new treatment for pancreatic cancer using SapC-DOPG, a nanotechnology drug delivery system. The treatment has shown promise in reducing tumor growth by 50-80% in animal models and aims to develop an effective immunotherapy treatment.
Researchers have identified a group of deregulated genes in pancreatic cancer that may serve as potential therapeutic targets. These long non-coding RNAs, when silenced, reduced tumor aggressiveness and characteristics such as proliferation and invasion.
A trial involving 1000 patients with Lynch syndrome found that a daily dose of resistant starch reduced cancers in other parts of the body by over half, particularly upper GI cancers. The effect persisted for 10 years after stopping the supplement.
Researchers discovered cancer cells produce a unique collagen that alters the tumor microbiome and promotes cancer progression. Loss of this collagen reduces cancer cell proliferation and boosts anti-tumor immune response, offering a potential therapeutic strategy.
Researchers at Cold Spring Harbor Laboratory have developed a rapid organoid screening test that can predict response to neoadjuvant chemotherapy in pancreatic cancer patients. This test may help optimize personalized treatment plans and improve patient outcomes.
Combination chemotherapy with FOLFIRINOX before surgery increased survival in patients with borderline resectable pancreatic cancer, outperforming FOLFIRINOX plus radiotherapy. The study demonstrated the effectiveness of neoadjuvant chemotherapy in improving outcomes for these patients.
Researchers used radiomics-based machine learning models to detect pancreatic cancer on prediagnostic CT scans, identifying it up to 386 days before clinical diagnosis. The AI model showed high accuracy and specificity, with a range of 94-98%, and was unaffected by image variations.
A new study found that most patients with pancreatic cancer diagnosed through regular screenings had early-stage disease, leading to long-term survival. The study suggests that surveillance programs can help detect precancerous conditions and cancers early, when they are most treatable.
A preclinical study by Cedars-Sinai Cancer and Johns Hopkins University has discovered a novel three-step treatment that disrupts the pancreatic tumor microenvironment in laboratory mice. The treatment, which combines anti-PD-1 immunotherapy antibody, FAKi, and CXCR4, prevents cancer metastasis and bolsters the immune system.
Researchers have discovered a key protein regulating pancreatic cancer cell growth and spread, which can be manipulated to reverse the process. Boosting levels of GREM1 has been shown to turn back aggressive tumours, making them easier to treat.
Researchers found that suppressing an enzyme called MSRA, which fixes oxidative damage to proteins, sparks the metastatic spread of pancreatic cancer cells. The discovery suggests that similar switches may exist in other cancers and lays the groundwork for redox-based targeted therapies.
A study published in Molecular Cell has identified a protein, MSRA, whose level of expression acts as a molecular switch between primary cancer growth and metastasis in PDA cells. The researchers found that high levels of MSRA expression keep the growing cells as part of the primary tumor, while low levels trigger metastasis.
A recent scientific review suggests that the oral microbiome may hold key answers to pancreatic cancer development, diagnosis, and treatment. The study found a distinct association between oral microbiome patterns and pancreatic tumors, with certain disease-driving bacteria identified in both.
Researchers from Japan and the US share new technologies and blood biomarkers to detect pancreatic cancer and identify high-risk individuals. The findings aim to decrease cancer mortality rates by developing attractive new methods for early diagnosis.